Biocon Biologics gets licence for COVID-19 antibody treatment
Biocon Biologics, a subsidiary of Biocon, on Monday said it has got a licence from US-based Adagio Therapeutics for an antibody therapy to treat and prevent COVID-19, for India and select markets. Adagio Therapeutics has granted an exclusive licence to the company to manufacture and commercialise an antibody treatment based on ADG20 for India and select emerging markets.
SaaS startup Gumlet raises $1.6M led by Sequoia’s Surge (Funding)
Gumlet, a SaaS startup providing new-age media delivery infrastructure to automate the media publishing pipeline, has raised $1.6 million in funding led by Sequoia Capital India’s Surge. Gumlet helps developers across the globe automatically resize and optimise their images and videos as per the end user’s device or browser, delivering high quality media at the lowest possible bandwidth.
Moj, ShareChat owner raises $145M at $2.8B valuation from Temasek, others (Funding)
Mohalla Tech, the parent company behind Moj and ShareChat, has raised $145 million as an extension of its Series F round. At a valuation of $2.88 billion, the investment has been led by Singapore state investor Temasek, Moore Strategic Ventures (MSV), along with participation from Mirae-Naver Asia Growth fund. This is an additional investment beyond the $502 million raised in April this year with which the startup joined the unicorn club.
D2C beauty brand MyGlamm raises Rs 355 Cr from Accel Partners, others (Funding)
Direct-to-consumer beauty brand MyGlamm has raised Rs 355 crore in fresh funding from Accel Partners, along with participation from existing investors, taking the total funds raised in this round to Rs 530 crore. MyGlamm had started its series C funding in March this year with a Rs 175 crore investment from Ascent Capital, Amazon, and Wipro.
